Migraine Drugs Market is expected to increase at a compound annual growth rate (CAGR) of 6.4% from 2025 to 2035
The market for migraine drugs market was estimated to be worth USD 5.9
billion in 2024 and is expected to grow at a compound annual growth rate (CAGR)
of 6.4% to reach USD 9.6 billion in 2035. Migraine medications provide a
variety of patient-specific therapeutic choices. The market is sustainable and
expanding since it is in line with the healthcare industry.
Migraine is a
prevalent and debilitating neurological condition marked by severe, recurrent
headaches that are frequently accompanied by light and sound sensitivity,
nausea, and vomiting. Prodrome, aura, attack, and post-drome are the four
stages that migraine symptoms can go through, affecting both adults and
children. Both acute abortive and preventive/prophylactic medications are used
in the therapy of migraines.
Request For Free Sample Pages @ https://www.xresearch.biz/request-sample-pages/migraine-drugs-market
GROWTH
DRIVERS
The market is
largely driven by the increasing prevalence of migraines, which raises the need
for efficient treatment. A JAMA Network report states that total migraine
incidence rose by 34% for men and 56% for women. Women between the ages of 20
and 29 experienced the greatest rate of rise, with 600 to 1,000 new cases per
100,000 women annually. The NCBI estimates that there were 1.1 billion migraine
cases worldwide in 2019, a 1.7% rise in prevalence between 1990 and 2019. Males
and those between the ages of 10 and 14 showed the greatest increase in
incidence, whereas females and those between the ages of 20 and 24 had the
highest prevalence and DALYs.
Global
healthcare costs skyrocketed from 7.4% in 2022 to a record high of 10.7% in
2023, according to Becker and WHO. Globally, the insurer-reported cost trend
for 2024 is expected to be 9.9%, while some areas will witness a more rapid
rise. The growth in health spending to a record high of USD 9 trillion, or
almost 11% of global GDP, was driven by a substantial increase in government
spending on health across all income levels.
MARKET
SEGMENTATION:
· By
Type- Acute/Abortive Treatment (Analgesic, Ergotamine, Triptans),
Preventive/P Treatment (Beta Blockers, Anti-serotonergic drugs,
anti-depressants, anticonvulsants, calcium channel blockers)
· By
Route of Administration- Oral, Injectable (Pre-filled Syringes, Vial)
· By
Distribution Channel- hospital pharmacies, retail pharmacies and online
pharmacies
· By
Region- North America, Europe, Asia Pacific, The Middle East and
Africa, South America
Global
Key Players:
· Novartis
AG
· AstraZeneca
· Amgen
Inc.
· Abbvie
· Glaxo
SmithKline plc
· Eli
Lilly and Compnany
· Abbott
Laboratories
· Teva
Pharmaceuticals Industries
· Pfizer
· Merck
& Co. Inc
· Bausch
Health Companies
· Janssen
Pharmaceutical Company
· Biohaven
Pharmaceutical Holding Company
· Endo
Pharmaceutical
· Other
Players
For More Information about this Report @
https://www.xresearch.biz/shop/migraine-drugs-market
About Us: -
xResearch is a market research and consulting
organization that uses unique data, expert analysis, and new technologies to
create trusted intelligence on industries. Our research is focused on
delivering an informed and impartial view on essential market data of industry,
and it is primarily driven by an in-depth study covering the following
parameters: Market Sizing and Forecasting, Market Segmentation, Competitive
Analysis, Strategic Assessment and Business Modelling.
Contact:
Company Name: xResearch
Contact Person: James Lin
Email: sales@xresearch.biz
Phone: +1 718-619-8140
Websites: https://www.xresearch.biz/

Comments
Post a Comment